Changes in Hong Kong stocks | Yingen Biotech (09606) rose more than 9% DB-1311 combined Pumitamig WCLC summary revealed first-line SCLC ORR reached 92.3%

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Yingen Bio-B (09606) rose more than 9%. As of press release, it had risen 8.48% to HK$183, with a turnover of HK$165 million.

According to the news, the World Lung Cancer Conference (WCLC) updated the B7-H3 ADC BNT324/DB-1311 combined PD-L1×VEGF-A double anti-PUMITAMIG phase IB/II data developed by Yingen BioNTech for advanced lung cancer: as of July 7, 2026, the overall objective response rate (ORR) of 71 evaluable patients with small cell lung cancer (SCLC) was 70.4%, including 92.3% for first-line, 77.3% for second-line patients, and 52.4% for third-line and above.

UBS previously indicated that DB-1311 (B7-H3 ADC) is expected to be the main valuation driver, predicting peak sales of RMB 38.3 billion, which is higher than the market consensus of RMB 28.6 billion. The bank believes that the market has yet to fully price upcoming key data, including DB-1311 combined PD-L1/VEGF bispecific antibody concept verification data for lung cancer (2026 WCLC) and non-lung cancer (ESMO 2026), and the submission of a global biological product licensing application (BLA) for HER2 ADC (DB-1303).